Antibodies

05 Jun 2017 New Monotherapy Data for Merck’s KEYTRUDA® (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting
05 Jun 2017 With More than One-Year Follow-Up, Merck’s KEYTRUDA® (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure
05 Jun 2017 LAG-3Ig (IMP321) demonstrates positive safety and efficacy qualities in breast cancer clinical trial
04 Jun 2017 Zymeworks Presents Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the American Society of Clinical Oncology Annual Meeting (ASCO 2017)
04 Jun 2017 Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual Meeting
04 Jun 2017 TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia at the 53rd Annual Meeting of the American Society of Clinical Oncology
04 Jun 2017 New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in Resected High-Risk Melanoma Patients Presented at ASCO
04 Jun 2017 Biosimilar trastuzumab candidate, CT-P6, shown to be similar in efficacy and safety to the reference trastuzumab
04 Jun 2017 First Presentation of Efficacy Data from CheckMate -204 Evaluating the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Demonstrates Anti-tumor Activity in Advanced Melanoma Patients with Brain Metastases
04 Jun 2017 New Data Show Durability of Response for Merck’s KEYTRUDA® (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor Type
04 Jun 2017 Longer Term Follow-Up Data with Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) to Be Presented at 2017 ASCO Annual Meeting
04 Jun 2017 With Nearly Three Years of Follow-Up, KEYTRUDA® (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared to Ipilimumab in Advanced Melanoma
04 Jun 2017 Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrated Promising Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer in Phase 2 CheckMate -142 Study
04 Jun 2017 Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy
04 Jun 2017 European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy
04 Jun 2017 Opdivo (nivolumab) Data in Patients with Advanced Cervical, Vaginal and Vulvar Cancers from Phase 1/2 CheckMate -358 Presented at ASCO
02 Jun 2017 AMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study Conducted by Velo Bio
02 Jun 2017 Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia
31 May 2017 Teva Announces Positive Results for Phase III Study of Fremanezumab for the Prevention of Chronic Migraine
31 May 2017 Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
31 May 2017 Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA® (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
30 May 2017 Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo (nivolumab) in Metastatic Cervical Cancer
29 May 2017 Apogenix Granted PRIME designation by European Medicines Agency for Asunercept to Treat Glioblastoma
27 May 2017 Harpoon Therapeutics Announces Completion of $45M Series B Financing
26 May 2017 Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive Phase 2 Data in People with HoFH

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top